Sentien Biotechnologies snags $12 mln Series A
Sentien Biotechnologies Inc, a biotechnology company focused on cell therapy, has raised $12 million in Series A funding. Boehringer Ingelheim Venture Fund USA Inc and BioInnovation Capital led the round with participation from Chiesi Ventures, MBL Venture Capital Co. Ltd and Mass Medical Angels.
4 April 2017•1 min read
